Clinical trials: Epithelial Tumor, Malignant
Malignant Mesothelioma, Metastatic Cancer
Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00899613
- Testing
- laboratory biomarker analysis, study of high risk factors
- Where
- France
- Volunteers
- 270 people
- Sponsor
- University Hospital, Caen
Neuroendocrine Neoplasm, Adenocarcinoma
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
The objective of the study is to create a common and unique platform for the acquisition of biological samples and, subsequently, the possible identification of predictive and prognostic biomarkers for young adults with…
- Trial name
- YOUNGSTER (NCT06337760)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- European Institute of Oncology
Nasopharyngeal Carcinoma
The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT
The purpose of this study is to verify that simultaneous integrated boost IMRT (SIB-IMRT) alone is non-inferior to SIB-IMRT combined with concurrent chemotherapy for low-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT01817023
- Testing
- SIB-IMRT, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 590 people
- Sponsor
- Chinese Academy of Medical Sciences
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/day in Japanese Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma.
- Trial name
- NCT01661179
- Testing
- Vandetanib 300mg
- Where
- 4 sites in Japan
- Volunteers
- 14 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced (Stage IV) Non-small Cell Lung Cancer (NSCLC)
Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study
This is a pilot study to test the hypothesis that biofeedback-mediated stress management (BFSM) training can be used to reduce distress and enhance quality of life in patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT01685346
- Testing
- biofeedback-mediated stress management (BFSM)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Renal Cell Carcinoma, Advanced Kidney Cancer
Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)
This prospective cohort study will investigate whether changes in circulating and urinary exosomal biomarkers (target exosomal miRNA) are associated with response to systemic treatment in patients with advanced renal cell…
- Trial name
- EXO-RENAL1 (NCT07406646)
- Testing
- Blood and Urine Sampling for Exosomal miRNA Analysis
- Where
- Slovenia
- Volunteers
- 91 people
- Sponsor
- Institute of Oncology Ljubljana
Head and Neck Neoplasms
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
The purpose of this trial is to study fluorodeoxyglucose-positron emission tomography (FDG-PET)-based dose escalation using intensity modulated radiation therapy (IMRT).
- Trial name
- NCT00135161
- Testing
- FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)
Previous studies confirmed locally advanced oral/oropharyngeal squamous cell carcinoma (LA OSCC or OPSCC) patients with a pathological response had higher probability of survival in neoadjuvant settings.
- Trial name
- NCT06009861
- Testing
- Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- Peking University Hospital of Stomatology
Adenocarcinoma of Lung, Stage IV
Lung Cancer Mutation Consortium Protocol
The primary objective of this protocol is to determine the frequency of oncogenic mutations in 1000 patients with advanced adenocarcinoma of the lung.
- Trial name
- NCT01014286
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- University of Colorado, Denver
NSCLC, Leptomeningeal Metastasis
Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis
A prospective, open-label, multi-center, single-arm study of Almonertinib combined With Bevacizumab for EGFR-mutant NSCLC patients with leptomeningeal metastasis.
- Conditions
- NSCLC, Leptomeningeal Metastasis, EGFR Activating Mutation
- Trial name
- ATTRACT (NCT04944069)
- Testing
- Almonertinib, Bevacizumab
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Lung Cancer
Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006469
- Testing
- carboplatin, paclitaxel, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medstar Health Research Institute
NSCLC Stage IV
Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy
This study is a multicenter, randomized controlled clinical trial to explore the preliminary efficacy and safety of treatment response adapted hybrid radiotherapy (LDRT and SBRT) in the first-line treatment of immunotherapy…
- Trial name
- NCT06313541
- Testing
- SBRT or LDRT, PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Fudan University
Laparoscopic Hepatectomy, Hepatocellular Carcinoma
Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection
Recent clinical experience showed that laparoscopic hepatectomy has advantages of minimally invasive compared to open liver resection, however, laparoscopic liver resection is still difficult and risky.
- Trial name
- NCT02131441
- Testing
- laparoscopic hepatectomy, open liver resection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Ovarian Cancer, Ovarian Neoplasms
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pegylated liposomal doxorubicin (PLD), a type of chemotherapy, is a standard treatment option for patients with platinum-resistant ovarian cancer.
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Fallopian Tube Cancer
- Trial name
- NCT05261490
- Testing
- maplirpacept (PF-07901801), Pegylated Liposomal Doxorubicin (PLD)
- Where
- 18 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Metastatic Renal Cell Carcinoma
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.
- Trial name
- CYTOSHRINK (NCT04090710)
- Testing
- Ipilimumab/ Nivolumab, SBRT + Ipilimumab/Nivolumab
- Where
- 7 sites in Australia, Canada
- Volunteers
- 66 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Head and Neck Squamous Cell Carcinoma
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
The purpose of this trial is to determine whether or not Cialis (tadalafil) administered to head and neck squamous cell cancer patients augments immune response.
- Trial name
- NCT00894413
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Carcinoma
Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy
This trial studies the ability of micro-ultrasound to detect and characterize prostate cancer tumors in patients undergoing radical prostatectomy (removal of the entire prostate and some of the tissue around it).
- Trial name
- NCT04299620
- Testing
- Digital Image Analysis, Radical Prostatectomy, Transrectal Ultrasound
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thyroid Cancer
Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma
The purpose of this study is to determine whether the prophylactic ipsilateral central lymph node dissection is equally effective in the management of papillary thyroid microcarcinoma(PTMC) to the bilateral central lymph node…
- Trial name
- NCT00795782
- Testing
- Prophylactic central lymph node dissection
- Where
- South Korea
- Volunteers
- 258 people
- Sponsor
- Samsung Medical Center
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer
This is a multicenter, open-label, phase II study to evaluate the safety, tolerability, clinical activity, and pharmacokinetics of ILKN421H in combination with pembrolizumab in participants with locally advanced or metastatic…
- Trial name
- NCT07452224
- Testing
- ILKN421H, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- iLeukon Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.